期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 68, 期 4, 页码 599-608出版社
SPRINGER
DOI: 10.1007/s00262-019-02299-8
关键词
Hepatocellular carcinoma; Trial; Immunotherapy; Biomarker
资金
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
- NCI
- Astra Zeneca
- Adaptive Biotechnologies
- Intramural Research Program of the NIH, NCI [ZIA BC 011343]
- NATIONAL CANCER INSTITUTE [ZICBC010685] Funding Source: NIH RePORTER
BackgroundCheckpoint inhibitors have recently been approved for the treatment of patients with hepatocellular carcinoma (HCC). However, biomarkers, which will help identify patients responding to therapy, are missing. We recently tested the combination of anti-CTLA4 treatment (tremelimumab) with loco-regional therapy in patients with HCC and reported a partial response rate of 26%.MethodsHere, we report updated survival analyses and results from our immune monitoring studies on peripheral blood mononuclear cells (PBMCs) and tumors from these patients.ResultsTremelimumab therapy increased CD4(+)-HLA-DR+, CD4(+)PD-1(+), CD8(+)HLA-DR+, CD8(+)PD-1(+), CD4(+)ICOS(+) and CD8(+)ICOS(+) T cells in the peripheral blood of the treated patients. Patients with higher CD4(+)PD1(+) cell frequency at baseline were more likely to respond to tremelimumab therapy. PD-1 expression was increased on alpha fetal protein (AFP) and survivin-specific CD8 T cells upon tremelimumab treatment. An increase of tumor infiltrating CD3(+) T cells were also seen in these patients. Immunosequencing of longitudinal PBMC showed that one cycle of tremelimumab significantly decreased peripheral clonality, while no additional effects were seen after loco-regional therapy.ConclusionIn summary, we observed a clear activation of T cell responses in HCC patients treated with tremelimumab and identified potential biomarkers which will help identify patients responding to immunotherapy with anti-CTLA4.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据